Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temsirolimus with Bortezomib, Rituximab, and Dexamethasone in Waldenström Macroglobulinemia and NHL
NCT01381692Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2011
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of temsirolimus in Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), sponsored by National Cancer Institute. Started Jul 2011; status: completed.
02
Drugs
temsirolimus
03
Conditions
Waldenström macroglobulinemia (WM)mantle cell lymphoma (MCL)follicular lymphoma (FL)marginal zone lymphoma (MZL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT01381692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01381692.